Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2006 1
2012 2
2014 1
2016 5
2017 8
2018 27
2019 16
2020 5
2021 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Valbenazine.
[No authors listed] [No authors listed] 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 37748010 Free Books & Documents. Review.
No information is available on the use of valbenazine during breastfeeding in humans. Based on animal studies, the manufacturer recommends that breastfeeding be avoided during valbenazine therapy and for 5 days after the final dose....
No information is available on the use of valbenazine during breastfeeding in humans. Based on animal studies, the manufacturer recom …
Valbenazine for Tardive Dyskinesia.
Freudenreich O, Remington G. Freudenreich O, et al. Clin Schizophr Relat Psychoses. 2017 Summer;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717. Clin Schizophr Relat Psychoses. 2017. PMID: 28742396 Review.
In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine. Valbenazine is a modified metabolite of the vesicular monoamine transporter 2 (VMAT-2) inhibitor tetrabenazine, which is approved for the treatment of the hyperk …
In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine. Valbenazine is a modi …
Valbenazine for the Treatment of Adults with Tardive Dyskinesia.
Gupta H, Moity AR, Jumonville A, Kaufman S, Edinoff AN, Kaye AD. Gupta H, et al. Health Psychol Res. 2021 Jun 18;9(1):24929. doi: 10.52965/001c.24929. eCollection 2021. Health Psychol Res. 2021. PMID: 35106396 Free PMC article. Review.
This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive dyskinesia in adults and needs to be evaluated with existing therapeutic approaches. ...Once symptom onset has occurred, these movement abno …
This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive …
Valbenazine for the treatment of tardive dyskinesia.
Müller T. Müller T. Expert Rev Neurother. 2017 Dec;17(12):1135-1144. doi: 10.1080/14737175.2017.1386556. Epub 2017 Oct 12. Expert Rev Neurother. 2017. PMID: 28971695 Review.
Valbenazine and particularly its metabolite inhibit vesicular monoamine transporter 2 function. Once daily intake of valbenazine ameliorated the severity of tardive dyskinesia. The chiral purity of valbenazine circumvents generation of the (-)alpha and (+) an …
Valbenazine and particularly its metabolite inhibit vesicular monoamine transporter 2 function. Once daily intake of valbenazine …
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F, Luther K, Talreja O. Khorassani F, et al. Am J Health Syst Pharm. 2020 Jan 24;77(3):167-174. doi: 10.1093/ajhp/zxz299. Am J Health Syst Pharm. 2020. PMID: 31974564 Review.
PURPOSE: The purpose of this review is to summarize the current evidence for valbenazine and deutetrabenazine use for the treatment of tardive dyskinesia (TD). SUMMARY: A literature search was conducted to gather relevant data regarding the use of valbenazine and de …
PURPOSE: The purpose of this review is to summarize the current evidence for valbenazine and deutetrabenazine use for the treatment o …
Valbenazine: First Global Approval.
Kim ES. Kim ES. Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Drugs. 2017. PMID: 28578484 Review.
Valbenazine (Ingrezza) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. ...This article summarizes the milestones in the develo …
Valbenazine (Ingrezza) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by N …
Clinical development of valbenazine for tics associated with Tourette syndrome.
Farber RH, Angelov A, Kim K, Carmack T, Thai-Cuarto D, Roberts E. Farber RH, et al. Expert Rev Neurother. 2021 Apr;21(4):393-404. doi: 10.1080/14737175.2021.1898948. Epub 2021 Apr 1. Expert Rev Neurother. 2021. PMID: 33682568 Review.
While there was a trend in the 6 completed trials toward greater improvement in valbenazine-treated versus placebo subjects on the primary efficacy endpoint (Yale Global Tic Severity Scale Total Tic Score), this difference did not reach statistical significance. Valbena …
While there was a trend in the 6 completed trials toward greater improvement in valbenazine-treated versus placebo subjects on the pr …
Valbenazine and Deutetrabenazine for Tardive Dyskinesia.
Touma KTB, Scarff JR. Touma KTB, et al. Innov Clin Neurosci. 2018 Jun 1;15(5-6):13-16. Innov Clin Neurosci. 2018. PMID: 30013814 Free PMC article. Review.
Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or discontinuation due to a risk of psychiatric decompensation. Valbenazine and deutetrabenazine were recently approved by the FDA for the treat …
Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or disconti …
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H, Henchcliffe C. Sarva H, et al. Expert Rev Clin Pharmacol. 2018 Mar;11(3):209-217. doi: 10.1080/17512433.2018.1429264. Epub 2018 Jan 23. Expert Rev Clin Pharmacol. 2018. PMID: 29338466 Review.
Valbenazine acts to decrease dopamine release, reducing excessive movement found in TD. ...Expert commentary: Two clinical trials assessing the efficacy of valbenazine have shown the reduction of antipsychotic-induced involuntary movement. ...
Valbenazine acts to decrease dopamine release, reducing excessive movement found in TD. ...Expert commentary: Two clinical trials ass …
Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L. Citrome L. Int J Clin Pract. 2017 Jul;71(7). doi: 10.1111/ijcp.12964. Epub 2017 May 12. Int J Clin Pract. 2017. PMID: 28497864 Free article. Review.
An additional warning and precaution is that valbenazine can prolong the ECG QT interval, however, the valbenazine product label does not contain any bolded boxed warnings or contraindications. ...Valbenazine is about 15 times more likely to result in a respo …
An additional warning and precaution is that valbenazine can prolong the ECG QT interval, however, the valbenazine product lab …
66 results